IMI - Call 16: Projects on Tuberculosis (TB) and Antimicrobial resistance (AMR)

IMI-2 (Innovative medicines initiative) has launched seven topics for projects to advance the RnD pipeline of new and innovative agents to address AMR. Deadline is October 24th, 2018.


A webinar explaining the topics was conducted July 6th. Click to see presentations, recording and list of participants.


Applicant consortia must include at least two independent legal entities established in different EU member states or associated countries of which one must be an EFPIA Company.


The evaluation process is single-stage. The deadline is October 24th, 2018.

IMI Webpage


Published Aug. 2, 2018 12:00 AM - Last modified Aug. 2, 2018 12:40 PM